Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
Proposed combination enhances Pfizer’s position as a leading company in oncology
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Subscribe To Our Newsletter & Stay Updated
